Inverse probability of censoring weighting for visual predictive checks of time-to-event models with time-varying covariates.

inverse probability weighting model diagnostics time-to-event models time-varying covariates visual predictive check

Journal

Pharmaceutical statistics
ISSN: 1539-1612
Titre abrégé: Pharm Stat
Pays: England
ID NLM: 101201192

Informations de publication

Date de publication:
11 2021
Historique:
revised: 17 02 2021
received: 07 08 2020
accepted: 26 03 2021
pubmed: 16 4 2021
medline: 27 1 2022
entrez: 15 4 2021
Statut: ppublish

Résumé

When constructing models to summarize clinical data to be used for simulations, it is good practice to evaluate the models for their capacity to reproduce the data. This can be done by means of Visual Predictive Checks (VPC), which consist of several reproductions of the original study by simulation from the model under evaluation, calculating estimates of interest for each simulated study and comparing the distribution of those estimates with the estimate from the original study. This procedure is a generic method that is straightforward to apply, in general. Here we consider the application of the method to time-to-event data and consider the special case when a time-varying covariate is not known or cannot be approximated after event time. In this case, simulations cannot be conducted beyond the end of the follow-up time (event or censoring time) in the original study. Thus, the simulations must be censored at the end of the follow-up time. Since this censoring is not random, the standard KM estimates from the simulated studies and the resulting VPC will be biased. We propose to use inverse probability of censoring weighting (IPoC) method to correct the KM estimator for the simulated studies and obtain unbiased VPCs. For analyzing the Cantos study, the IPoC weighting as described here proved valuable and enabled the generation of VPCs to qualify PKPD models for simulations. Here, we use a generated data set, which allows illustration of the different situations and evaluation against the known truth.

Identifiants

pubmed: 33855777
doi: 10.1002/pst.2124
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1060

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

Björnsson MA, Simonsson US. Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration. Br J Clin Pharmacol. 2011;71(6):899-906.
Huh Y, Hutmacher MM. Application of a hazard-based visual predictive check to evaluate parametric hazard models. J Pharmacokinet Pharmacodyn. 2016;43(1):57-71.
Vu TC, Nutt JG, Holford NH. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. Br J Clin Pharmacol. 2012;74(2):284-295.
Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185-202.
Robins JM. Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate markers. Paper presented at: Proceedings of the Biopharmaceutical Section; 1993; American Statistical Association.
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779-788.
Willems S, Schat A, van Noorden M, Fiocco M. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator. Stat Methods Med Res. 2018;27(2):323-335.
Friberg L, De Greef R, Kerbusch T, Karlsson M. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther. 2009;86(1):84-91.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
Sarkar K, Chowdhury R, Dasgupta A. Analysis of survival data: challenges and algorithm-based model selection. J Clin Diagn Res. 2017;11(6):LC14-LC20.
Team RC. R: A language and environment for statistical computing.
Therneau T, Lumley T. R survival package; 2013.
Fisher LD, Lin DY. Time-dependent covariates in the cox proportional-hazards regression model. Annu Rev Public Health. 1999;20(1):145-157.
Henderson R. Joint Modelling of Longitudinal and Event Time Data. Hoboken, New Jersey, USA: Wiley StatsRef: Statistics Reference Online; 2014.

Auteurs

Christian Bartels (C)

Novartis Pharma AG, Basel, Switzerland.

Thomas Dumortier (T)

Novartis Pharma AG, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH